Oxford, UK – 01 June 2012. OGT has launched the Oligome, a comprehensive database of more than 10 million oligonucleotide probes designed to the latest release of the human genome. This invaluable resource makes it possible to provide custom-designed oligonucleotide arrays for array-based comparative genomic hybridization (aCGH) on request, within a very short space of time and at a lower cost than would normally be expected for a custom array.
OGT’s 60mer oligonucleotide microarrays are fabricated using inkjet technology with base-bybase synthesis that allows high precision feature placement, and denser coverage of regions of interest. OGT offers custom-designed CGH arrays for analysing chromosomal abnormalities within focused areas of the human genome at high resolution. As part of the free design service, scientists can simply provide OGT their regions of interest. OGT then performs the Oligome based bioinformatics required to design, fabricate and deliver the desired focussed arrays.
“In the past, we have provided custom-made arrays focusing on certain genomic regions by processing the sequence of interest,” said Dr Volker Brenner, senior computational biologist at OGT. “Now that we have compiled the Oligome, we can easily query the database and produce the array design much more quickly, and at a lower cost for the customer.”
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.Read
CytoSure™ NGS – Combining the benefits of microarrays and NGS in a single assay.Read